OraSure CEO Stephen Tang discussed the firm's plans for international expansion, while Meridian CEO Jack Kenny said the firm needs to develop a new MDx platform.
Among the updates provided Wednesday, Quidel's CEO noted the firm's growing presence in point-of-care markets, while PerkinElmer discussed plans for its Vanadis test.
The firm's CEO told investors at the JP Morgan Healthcare Conference that in addition to driving growth of its sepsis test in the US, Accelerate is eyeing expansion into China.
The company plans to focus on increasing its NIPT reimbursement as well as on pharmaceutical deals for its oncology test and launching a kidney transplantation test.
Abbott CEO Miles White is bullish on the firm's Alinity systems, while Quest and LabCorp see acquisitions as the likely result of further PAMA-related cuts.
The company is also looking to expand the use of its FDA-approved ClonoSeq assay, which has US FDA approval for MRD detection in acute lymphocytic leukemia and multiple myeloma.
At JP Morgan, Qiagen CEO Peer Schatz discussed a new digital PCR system and handheld reader for TB testing; Qiagen's acquisition of N-of-One; and its new sample prep system.
Siemens Healthineers CEO Bernd Montag talked about the positive impact the firm's Attelica system is having on its revenues, while Bruker discussed plans for the BioTyper platform and assays in the pipeline.
The firm's fourth quarter preliminary revenues increased by 11 percent to $865 million year over year, while full-year revenues jumped by 21 percent to $3.3 billion.
CEO Kim Popovits discussed three strategic imperatives for the coming year: increasing penetration in established markets, broadening global access, and continuing to diversify its portfolio.
